Isaac Manke, PhD
Isaac Manke, PhD is an experienced life sciences venture capitalist and represents Acorn BioVentures on the board.
He joined Acorn BioVentures as a General Partner in 2020. Previously, he was a General Partner at New Leaf Venture Partners, where he invested across private and public biotechnology companies for 11 years.
Prior to his venture capital career, he was an analyst and held roles that included Associate Equity Analyst, in the Global Biotechnology Equity Research group at Sanford C. Bernstein and in the Biotechnology Equity Research group at Deutsche Bank. Previously, he was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm.
In his earlier career as a research scientist at the Massachusetts Institute of Technology (MIT) Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of the “2003: Signaling Breakthroughs of the Year”. These discoveries also resulted in four issued patents.
Isaac received a BA in Biology and a BA in Chemistry at Minnesota State University (Moorhead), and a PhD in Biophysical Chemistry and Molecular Structure at MIT.